Gene · 200424
TET3: tet methylcytosine dioxygenase 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TET3: tet methylcytosine dioxygenase 3. Genes, record 200424. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/200424
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43151 | Methylcytosine dioxygenase TET3 | 1,795 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents16
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025254779 A1 | 2025-12-11 | 3 | O43151 | Espacenet |
| WO 2025224162 A1 | 2025-10-30 | 3 | O43151 | Espacenet |
| EP 4640827 A1 | 2025-10-29 | 3 | O43151 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 13053 | O43151 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 13053 | O43151 | Espacenet |
| WO 2024256581 A1 | 2024-12-19 | 47 | O43151 | Espacenet |
| KR 1020240011120 A | 2024-01-25 | 601 | O43151 | Espacenet |
| JP 2024501383 A | 2024-01-11 | 625 | O43151 | Espacenet |
| JP 2023529844 A | 2023-07-12 | 86 | O43151 | Espacenet |
| KR 1020230021081 A | 2023-02-13 | 3 | O43151 | Espacenet |
1 to 10 of 16
See all 16 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,762
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TET3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 19 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 14 | 2025 |
| R01HG006827 | Labeling and sequencing of 5hmC and 5mC in DNA-Renewal | 12 | 2025 |
| R35CA210043 | The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancer | 9 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 7 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P30CA023168 | Cancer Center Support Grant | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,762Source NIH's project files
See all 1,762 nih grantsPapers2,594
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TCR-mTORC1 signaling promotes epigenetic stabilization of Foxp3 expression in regulatory T cells via TET protein translation. | Proc Natl Acad Sci U S A | 2026 | 42809396 | PubTator, text mining | PubMed |
| Further delineation of 2p13.2-p11.2 deletion syndrome by optical genome mapping. | Neurogenetics | 2026 | 42762249 | PubTator, text mining | PubMed |
| Epigenetic alterations in rheumatoid arthritis: multilayer mechanisms and translational opportunities. | Front Immunol | 2026 | 42746461 | PubTator, text mining | PubMed |
| Elevated DNA 5-hydroxymethylation promotes chondrocyte differentiation via TET-mediated epigenetic downregulation of hTERT in human mesenchymal stem cells. | Histochem Cell Biol | 2026 | 42680856 | PubTator, text mining | PubMed |
| Validating raloxifene-mediated restoration of DNMT-TET epigenetic balance in breast and lung cancer. | Cancer Treat Res Commun | 2026 | 42612286 | PubTator, text mining | PubMed |
| Clinical Significance of SOX2 Promoter Methylation in Breast Cancer Prognosis. | Cancer Control | 2026 | 42555815 | PubTator, text mining | PubMed |
| Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3-CXCL8 Axis. | Adv Sci (Weinh) | 2026 | 42531706 | PubTator, text mining | PubMed |
| TET Enzymes as Epigenetic Integrators in Intestinal Immunity, Inflammation, and Disease. | J Pers Med | 2026 | 42506101 | PubTator, text mining | PubMed |
| Biomarkers for Diabetic Peripheral Artery Disease: An Integrated Review and Clinical Perspective. | Diabetes Metab Res Rev | 2026 | 42402062 | PubTator, text mining | PubMed |
| Increased TET3 expression associates with proinflammatory cytokines and reduced 5-hydroxymethylcytosine in periapical lesions. | Clin Oral Investig | 2026 | 42377549 | PubTator, text mining | PubMed |
1 to 10 of 2,594
See all 2,594 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/200424
GET https://conductscience.org/api/genes/v1/200424/patents